Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 6.49% is 89% above its 5-year average of 3.44%, near the high end of its 5-year range (-36.07%–13.27%).
21.56% above its 12-month average of 5.34%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 4.30%.
NET PROFIT MARGIN
6.49%
NET PROFIT MARGIN AVG TTM
5.34%
NET PROFIT MARGIN AVG 3Y
3.18%
NET PROFIT MARGIN AVG 5Y
3.44%
NET PROFIT MARGIN AVG 10Y
2.89%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+21.56%
CURRENT VS 3Y AVG
+104.23%
CURRENT VS 5Y AVG
+88.85%
CURRENT VS 10Y AVG
+124.61%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 731 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
The Joint Corp.
Market Cap
$102.85M
Net Profit Margin
6.49%
TTM Avg
5.34%
3Y Avg
3.18%
5Y Avg
3.44%
Market Cap
$102.86M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$102.84M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1167.97%
5Y Avg
-1200.09%
Market Cap
$104.68M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$105.13M
Net Profit Margin
-72.28%
TTM Avg
-110.67%
3Y Avg
-76.27%
5Y Avg
-63.46%
Market Cap
$107.65M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-1332.08%
Market Cap
$97.84M
Net Profit Margin
-4477.08%
TTM Avg
-2757.42%
3Y Avg
-1378.71%
5Y Avg
-931.09%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Joint Corp. (JYNT) | $102.85M | 6.49% | 5.34% | 3.18% | 3.44% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $102.86M | 0.00% | 0.00% | 0.00% | 0.00% |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.84M | 0.00% | 0.00% | -1167.97% | -1200.09% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | 0.00% | 0.00% | 0.00% | 0.00% |
| Definitive Healthcare Corp. (DH)vs › | $105.13M | -72.28% | -110.67% | -76.27% | -63.46% |
| PolyPid Ltd. (PYPD)vs › | $98.56M | 0.00% | 0.00% | 0.00% | 0.00% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.65M | 0.00% | 0.00% | 0.00% | -1332.08% |
| Korro Bio, Inc. (KRRO)vs › | $97.84M | -4477.08% | -2757.42% | -1378.71% | -931.09% |
| Conexeu Sciences Inc. (CNXU)vs › | $98.07M | N/A | N/A | N/A | N/A |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $97.13M | -3585.62% | -2039.39% | -2803.76% | -1916.79% |
Operating Margin
2.5%
Net Profit Margin
6.5%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 4.30% |
| 2026-03-31 | 8.77% |
| 2025-12-31 | 6.53% |
| 2025-09-30 | 6.39% |
| 2025-06-30 | 0.70% |
| 2025-03-31 | 7.40% |
| 2024-12-31 | 7.09% |
| 2024-09-30 | -10.48% |
| 2024-06-30 | -28.52% |
| 2024-03-31 | 7.77% |
| 2023-12-31 | -36.07% |
| 2023-09-30 | -2.43% |
| 2023-06-30 | -1.09% |
| 2023-03-31 | 8.22% |
| 2022-12-31 | 1.97% |
| 2022-09-30 | 2.76% |
| 2022-06-30 | -3.50% |
| 2022-03-31 | 0.02% |
| 2021-12-31 | -1.63% |
| 2021-09-30 | 9.23% |
| 2021-06-30 | 13.27% |
| 2021-03-31 | 13.19% |
| 2020-12-31 | 62.41% |
| 2020-09-30 | 10.41% |
| 2020-06-30 | 0.92% |
| 2020-03-31 | 5.97% |
| 2019-12-31 | 9.31% |
| 2019-09-30 | 4.85% |
| 2019-06-30 | 4.14% |
| 2019-03-31 | 8.92% |
| 2018-12-31 | 9.20% |
| 2018-09-30 | -1.88% |
| 2018-06-30 | -0.57% |
| 2018-03-31 | -5.45% |
| 2017-12-31 | -3.08% |
| 2017-09-30 | -6.17% |
| 2017-06-30 | -16.81% |
| 2017-03-31 | -29.03% |
| 2016-12-31 | -99.65% |
| 2016-09-30 | -47.73% |
| 2016-06-30 | -65.57% |
| 2016-03-31 | -82.65% |
| 2015-12-31 | -89.85% |
| 2015-09-30 | -40.04% |
| 2015-06-30 | -54.16% |
| 2015-03-31 | -75.91% |
| 2014-12-31 | -124.90% |
| 2014-09-30 | -11.14% |
| 2014-06-30 | -7.72% |
| 2014-03-31 | -8.45% |
| 2013-12-31 | -0.02% |
| 2013-09-30 | 2.89% |
